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and these costs are increasing compared to year to year. Policy interventions did not 
effected biotechnological medicine sales negatively. While big differences between 
the biotechnological and non-biotechnological medicine box sales will continue, 
the gap between the biotechnological and non-biotechnological medicines total 
amount will be closer.
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Objectives: There are concerns that the time taken to develop innovative new drugs 
is increasing, delaying access to and increasing the costs of new medicines. Both the 
clinical trial stage and regulatory approval stage for new drugs are important compo-
nents of overall development time, and we sought to determine whether the length 
of either of these stages is increasing, using new anti-viral drugs launched in the UK 
as a case-study. MethOds: New anti-viral drugs launched in the UK between 1981 
and 2013 were identified from the British National Formulary. Initiation of clinical 
development was determined from Pharmaprojects (Informa Healthcare) and Medline 
searches; the Investigational New Drug Application or first report of phase I trials 
was taken as the start of clinical development, whichever was earlier. Regulatory 
submission and approval dates were obtained from the European Medicines Agency 
and UK Medicines and Healthcare Regulatory Agency. Results: 43 new anti-viral 
drugs were launched in the UK between 1981 and 2013, with a mean time from start 
of clinical trials to approval of 6.4 years. This period increased from 4.8 years for drugs 
launched 1981-93, to 6.0 years for those launched 1994-2003, and 7.9 years for those 
launched 2004-2013; and a statistically significant positive linear trend was observed 
(r= 0.47). The mean time from regulatory submission to approval was 1.1 years, but 
no significant linear trend was seen for this time period (r= 0.20). New drugs for HIV 
typically spent less time in clinical development than other anti-viral drugs (mean 
5.7 vs 7.3 years, p= 0.049). However clinical development times for HIV and other anti-
viral drugs increased at a similar rate. cOnclusiOns: For anti-viral drugs launched 
in the UK, the time spent in clinical development has increased markedly since the 
1980s, and this increase is not related to increasing time taken for regulatory approval.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. Total phar-
maceutical market reached US $ 8 billion in last 10 years. HTP improved health 
coverage and access to health services, additional policies are implemented by MoH 
for controlling this increasing trend on pharmaceutical consumption. The aim of 
this analysis is to understand the impact of selected 5 major policy changes to total 
pharmaceutical consumption in between 2002-2012. MethOds: 132 months sales 
data with segmented regression analysis for interrupted time series were used. 
International reference pricing of pharmaceuticals (RF), mandatory reimbursement 
dossier submission for new molecules, new indications and line extensions with 
medical and economic evaluations (MRDS), auditing for good manufacturing prac-
tice (GMP), family physician system (FP) and compulsory medical service for physi-
cians (CMS) were selected as five major policies that may affect cost, demand and 
supply of pharmaceuticals. We analyzed possible breaks in trends prior and after 
the implementation of 5 selected policies of the HTP. The analysis was conducted for 
cost (CS) and unit sales (US) for all pharmaceutical products. The Durbin-Watson d 
statistics of SPSS version 20.0 was used as a test for serial correlation of error terms. 
Shift in slope with p< 0.05 was considered as statistically significant. Results: All, 
except for RF policy changes, had a negative impact on the trends for CS. RF policy 
did not reverse the trends in CS and US however it slowed positive trend in CS signif-
icantly down. All policies hindering impact on the increasing trend in US. However, 
only RF and CMS policies reached statistically significant level. cOnclusiOns: 
Policies within the HTP framework were successful to control pharmaceutical 
expenditures while improving access to health care. International reference pric-
ing has a limited impact on controlling growth of pharmaceutical market.
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Objectives: To provide an overview of biosimilars uptake in Europe and assess 
policies and initiatives that might boost uptakes of biosimilars in European coun-
tries. MethOds: A literature review was conducted from European and national 
health authorities websites, Generics and Biosimilars Initiative (GaBi) website, 
Medline® database, and available grey literature. Results: To date, 17 biosimi-
lars were granted marketing authorization throughout the European Union and 
the European Medicines Agency released 9 product-specific biosimilar guidelines. 
Recent approval of the first monoclonal antibody biosimilar of infliximab dem-
onstrates the evolution of the European regulatory framework over time allowing 
approval of structurally complex molecules. Despite Europe has been a pioneer in 
this regulatory path, biosimilars uptake still remains limited (about 30% to 50% 
volume uptake) with modest price discounts from the originators (15% to 30%). If 
Germany authorized substitution of biological products produced by a same manu-
facturer in 2011, none of the Members States had allowed substitution of biological 
products from different manufacturers so far. With adoption of the 2014 social 
Objectives: To assess the global economic consequences for French hospitals of 
the European Commission (EC) decision to strengthen administration conditions 
of intravenous iron products (IIP) (iron sucrose (IS) and ferric carboxymaltose (FC)) 
due to safety concerns. Following this EC decision, in February 2014, French Health 
Authorities decided to give a hospital-restricted status (HRS) to IIP. MethOds: We 
compared, in acute care (medicine, -surgery-obstetrics) hospitals, IIP consumption 
and expenditure (extracted from SAP software) before (2012 vs. 2013) and before-after 
(02/2013-04/2013 vs. 02/2014-04/2014) they had a HRS, and the number of diagnosis-
related group “sessions of chemotherapy for non-tumor disease” (DRG-CNTD) linked 
to anemia (Technical Agency of Information on Hospitals data). Results: 20 hospitals 
were included. Before they had a HRS, IIP global consumption in volume increased by 
9.6% (i. e. € 171,022 spent more) in a year. After IIP had a HRS, the increase was 16.7% 
(i. e. € 164,338 spent more) in 3 months (02/2013-04/2013 vs. 02/2014-04/2014). 23.7% of 
the increase was attributable to day hospital admissions (DHA) and 4.4% to dialysis 
units. FC consumption was 23.9% higher (i. e. € 188,838 spent more) in 2014 compared 
to 2013, whereas IS consumption was 16.4% lower (i. e. € 24,500 spent less). DHA in 
DRG-CNTD linked to anemia increased by a factor of 1.8. cOnclusiOns: DHA as 
part of the DRG-CNTD is the only way to finance this additional hospital activity (no 
additional funding for traditional hospital care). FC’s cost of daily treatment (€ 120 
to € 150) is about 20 times IS’s (€ 5.2 to € 7.8), while a single tariff is allocated for the 
DRG-CNTD (drug case-mix: € 62, whatever the drug). Costs of the FC increasing use 
to manage anemia may be offset by administration of other drugs, or the DRG-tariff 
should be adjusted. Another alternative would be to implement a tender between IIP, 
taking into account the cost-effective ratio of each drug.
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Objectives: The increase in PBS expenditure over the past two decades led to 
the Australian Government implementing several cost containment measures. The 
objective of the present study was to investigate the impact of these reforms on PBS 
prescribing volumes and expenditure. MethOds: Data retrieved from Medicare 
Australia’s PBS Statistics database provided monthly government expenditure (ben-
efit) and prescription volume (service) data. Segmented linear regression models 
were used to analyse the time series data starting from 1 January 1992 to 31 March 
2012. In each segment, between implementing the cost containment measures, two 
parameters, the level and trend were used to estimate the impact of the interven-
tion. A lag of 12 months was applied to adjust for seasonality and forward stepwise 
eliminations were applied to obtain a parsimonious model. Seven cost containment 
measures were investigated: the economic evaluation requirement for drug listing 
(1/01/1993), re-supply limits (1/11/1994), two co-payment increases (1/01/1997 & 
1/01/2005), therapeutic group premium (TGP) policy (1/02/1998), safety net 20-day 
rule (1/01/2006), and price reductions in multiple brand drugs in Formulary 2 (F2) 
(1/08/2008). Results: All interventions except the re-supply limits policy were 
found to have a significant impact on PBS services or benefits. Reductions in the 
services and benefits trend were observed in two measures, the TGP policy and 
safety net 20-day rule while a reduction in the services trend was observed for 
the economic evaluation requirement measure. No significant trend changes were 
observed in the post F2 price reductions while higher co-payments resulted in a 
reduction in the level of services followed by an increase in the trend of services and 
benefits. cOnclusiOns: Many of the cost containment measures implemented 
in Australia have been effective in containing cost. Among these measures, the 
safety net 20-days rule was estimated to be the most effective in reducing drugs 
utilisation and expenditure.
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Objectives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. The top 100 medicines, annual average highest 
amount of sales of between 2008-2013, had one to four of the total pharmaceutical 
market value in 2013. We aimed to examine the status of biotech-medicines in the 
first 100 medicine’s and evaluate the effects of policy interventions on these medi-
cine sales. MethOds: While pharmaceutical sales data were obtained from the IMS 
Health-Turkey data base, prices and characteristics of medicines were obtained from 
the Turkish Medicine and Medical Devices Agency data bases. Each group (biotech/
nonbiotech-medicines) was analyzed using TRAMO and SEATS method. Results: 
19 medicines are biotechnological. In 2009 compared to 2008 while biotech-med-
icines amount increased by 43.8%, nonbiotech-medicines amount increased by 
14.2%. In subsequent years, an increase over the previous year is observed at lower 
rates for biotech-medicines. This total amount has decreased compared to previous 
years for nonbiotech-medicines. 2014 and 2015 for the consumption of biotechno-
logical medicines was estimated to be around 9 million boxes, expenditure for 2014 
of 1360 million Turkish Liras (TL) and 2015 million TL for the year 2015. On the other 
hand, non-biotechnological medicines consumption would be approximately 185 
million boxes and for the year 2014 2225 million TL, for the year 2015 2280 million 
TL are projected. cOnclusiOns: Biotechnological medicines have high unit costs 
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Objectives: In 2009, Greece entered into one of the most serious economic down-
turns in its modern history. In May 2010, the country was put under the supervi-
sion of Troika (EU, ECB and IMF). Retail pharmaceutical market with size c. a. € 6.5 
bn in retail prices for 2009 (public pharmaceutical expenditure € 5.2 bn), was one 
of the main targets for change through the implementation of new policies and 
drastic spending cuts. The purpose of this study was to measure the impact that 
these new policies for pharmaceutical spending had and how this was attributed 
to the levers of price, market volume and product mix. MethOds: An economic 
model was used, based on IMS Hellas’ and Hellenic Statistical Authority data, 
to measure the contribution that (a) price; (b) market volume; and (c) product 
mix had on the reduction in the size of the retail market for pharmaceuticals in 
the period 2009-2014. The detailed approach decomposes the market change, as 
measured in values, into those attributed to (a) price (assuming market volume 
and product mix are constant); (b) market volume (assuming prices and product 
mix are unchanged); (c) product mix. Results: The analysis indicated that, the 
major contributor in the reduction of the pharmaceutical market size was the 
price of medicines. It has been estimated that 87% of the reduction (> € 1.2 bn) is 
coming from price. Volume contributed an additional c. a. 38% (> € 0.5 bn) in the 
reduction of the size but, at the same time, it was partially offset from substitu-
tion with pricier medicines. cOnclusiOns: Price was the major driver for the 
reduction in the size of the retail pharmaceutical market during the period of 
crisis. Volume had an impact as well but it was partially offset by switch towards 
more expensive medicines.
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Objectives: The “liste-en-sus” was implemented within the framework 
of the HPST [1] law. One of its objectives was to ensure access to highly-priced 
innovative medicines in hospital settings without distorting the Diagnostic-
Related Groups (DRG). The objective of this research is to analyse the degree of 
innovation of the medicines included in the “liste-en-sus”. MethOds: Starting 
from the ATIH [2] database, an initial analysis consisted of identifying all the 
Health Technology Assessments (HTAs) for each product included in the “liste-
en-sus” available on the HAS website [3] . Then, for each HTA, the following infor-
mation was collected: assessment date, SMR [4] and ASMR [5] scores. Results: 
The liste-en sus includes 123 medicines. 21% have no HTA available. Another 19% 
were last evaluated before 2004. Among the medicines which had undergone an 
HTA since 2004, 7% were granted an ASMR I, 27% an ASMR II, 22% an ASMR III, 
8% an ASMR IV, 36% an ASMR V. In other terms, amongst the medicines which 
have undergone an HTA in the last 10 years, about 45% of them were deemed 
non-innovative (ASMR IV/V). Those medicines mainly consist in antihemorrhagics 
(27%), antianaemics (18%), antineoplastics (15%) and immune sera and immuno-
globulins (15%)[6] . Although they are not innovative, those medicines are only 
used in a proportion of patients and are thus likely to distort DRG. To put these 
results into perspective, since 2005, 92% of evaluated medicines were granted an 
ASMR IV/V [7]. cOnclusiOns: Looking at the list-en-sus’ objectives, the most 
decisive criterion seems to be more stability of the DRG rather than access to 
innovative medicines; however a higher proportion of the medicines in the liste-
en-sus are innovative.
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Objectives: To establish the key policy areas that will drive the establishment 
of a sustainable biosimilar medicines market. To outline the benefits that these 
will bring to Physicians, Payers, Patients, and Industry, with particular focus 
on the benefits for European National Health systems. MethOds: 71 qualita-
tive in-depth interviews were conducted across 7 European markets: France, 
Germany, Hungary, Italy, Poland, Spain and the UK, collecting insight from 
experts and policy influencers at pan-European, National and Regional levels, 
Physicians, Payers, Pharmacists, Patients, and Industry. Quantitative modelling 
used a systems dynamics approach with in-depth analysis of 3 representative 
biologic products: trastuzumab, bevacizumab, and adalimumab. Dynamics were 
based on a delphi panel of expert opinions. The five forces of supplier power, buyer 
power, impact of new entrants, impact of substitutes, and competitive rivalry 
were addressed. A ranking of the attractiveness of policy combinations from a 
sustainability and benefit perspective was made based on a biosimilar medicines 
market “Sustainability Index” and the calculation of the magnitude of the ben-
efits (cost savings, additional patients treated) that the policy combination was 
likely to produce. Results: The qualitative analysis has shown that a European 
biosimilars medicines market based on stakeholder and policy alignment in four 
key areas (1. education and understanding, 2. experience and use, 3. sustainable 
pricing, 4. rational decision making) will be sustainable and deliver benefits to 
all stakeholders. The quantitative analysis demonstrated that the most efficient 
policy combination, measured in terms of the sustainability index, was the same 
for all 3 molecules and would deliver cumulative 10 year cost savings of between 
24% and 26%. cOnclusiOns: Greater stakeholder alignment and the combina-
tion of specific policies will increase the sustainability of the European biosimilar 
medicines market. A sustainable biosimilar medicines market will deliver signifi-
cant benefits to all stakeholders.
security funding law, France is becoming the first country to allow biosimilars sub-
stitution when initiating treatment course. To encourage biosimilars substitution, 
the Norwegian Medicines Agency announced in 2013 the funding of clinical studies 
with infliximab originator and biosimilars in which patients would be switched 
from originator to biosimilars forth and back. Moreover, increased price discounts 
of about 40% were applied for infliximab in Norway. By 2020, expected savings 
for biosimilars are estimated around € 12-33 billion in big EU5, Poland, Romania, 
Sweden. cOnclusiOns: While patent cliff of major biologic drugs is expected on 
the next 5 years, initiatives to reassure physicians to prescribe biosimilars and 
implementation of substitution rules, even if still raising some reluctance, might 
contribute to boost biosimilar uptake in Europe. Price competition will impose 
manufacturers of branded biologics to adopt new pricing strategies.
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Objectives: In Turkey, a medicine reference pricing system has been in use since 
2004. The price of pharmaceuticals is determined by the acceptance of the lowest 
ex-factory price in the reference countries (Greece, France, Italy, Portugal, Spain). We 
aimed to examine the first 100 medicine’s, having the annual maximum amount 
on the average Turkish Lira (TL) based medicine sales between the years 2008-2013 
which have 25.1% value in the total pharmaceutical market, reference price changes 
in these period. MethOds: While pharmaceutical sales data were obtained from 
the IMS Health-Turkey data base, medicine prices were obtained from the Medicine 
Price List published by Turkish Medicines and Medical Devices Agency. Results: In 
2008, the top 100 medicines in determining the price of most of Italy were taken as 
the reference country, followed by Spain and Greece. In 2013 while Greece is taken as 
the reference country more common; France and Italy are to follow. In 2008, only one 
medicine’s price increased, and only one medicine’s price decreased because of the 
reference price. In 2009 and 2010 price increases did not seen. In 2009, 8 and in 2010, 
30 medicines prices had decreased. In 2011, 2012 and 2013 totally 27 medicines refer-
ence prices had increased. 21 medicine’s price in 2011, 20 medicine’s price in 2012 
and 24 medicine’s price in 2013 had decreased. While mostly France (13 medicines) 
connected to the reference price increases, mostly Greece (58 medicines) has been 
based reference price drop in the analyzed period. cOnclusiOns: The application 
of reference prices, medicine prices to be reduced to a large extent. Greece based 
reference price decreases are observed to be mainly from the year 2010. The reason 
for this is considered as the economic crisis in Greece and the agreement with the 
IMF, EU and ECB, the Greek government at cost-containment.
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Objectives: External price referencing (EPR) is a method to control pharmaceutical 
prices, wherein decision-makers specify a basket of countries, whose prices they 
use to inform their national target price. EPR is practiced frequently worldwide, 
though countries vary substantially in how they execute EPR. The objective of our 
pioneer collaborative health policy research initiative was to analyse how EPR is 
used in Middle East countries, and assess whether EPR results in narrower price cor-
ridor for innovative pharmaceuticals compared to non-pharmaceutical services not 
subjected to EPR. MethOds: In Q1 2014, we conducted a survey on EPR regulations, 
and collected prices of 16 innovative pharmaceuticals and 10 non-pharmaceutical 
services in six Middle East countries (Egypt, Jordan, Kuwait, Lebanon, Saudi Arabia, 
UAE). Prices in local currency were converted to USD by using market exchange 
rates. Maximum and minimum prices of each pharmaceutical and non-pharmaceu-
tical technology were compared to mean prices in the study countries. Results: 
EPR regulations are most stringent in Egypt and Saudi Arabia (largest study coun-
tries), mandating the lowest pharmaceutical price out of a basket comprising more 
than 25 countries each. By contrast, Kuwait references the country of origin only. The 
average price corridor is +/-38% for pharmaceuticals and +/-78% for outpatient and 
hospital services compared to mean prices. cOnclusiOns: EPR results in narrower 
price corridor for innovative pharmaceuticals compared to other health care ser-
vices. Prices of innovative pharmaceuticals are the lowest in Egypt and Saudi Arabia, 
and the highest in Kuwait, indicating the importance of population size and EPR 
implementation on drug price levels. However, EPR results in higher pharmaceutical 
prices in lower income countries compared to non-pharmaceutical services, which 
may limit timely access of patients to new medicines in these countries compared 
to global markets. Stakeholders should understand the implications of EPR and 
develop solutions to prevent its negative consequences.
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